|
|
||||||||
Are Important Factors in the Pathogenesis of Murine Recurrent Herpetic Stromal Keratitis
1 From the Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri; and the 2 Department of Ophthalmology, Tokyo Medical College Hospital, Japan.
| Abstract |
|---|
|
|
|---|
in recurrent herpetic stromal keratitis (HSK), the
cytokine content and the effects of anti-cytokine antibodies on mouse
corneas with the disease were examined.
METHODS. Competitive reverse transcriptionpolymerase chain reaction and
enzyme-linked immunosorbent analyses of IL-1
and TNF-
content
were performed on corneas removed 3, 5, 7, 10, 14, and 21 days after
latently infected NIH mice were irradiated with UV-B light to
reactivate herpes simplex virus (HSV). In separate experiments, mice
were injected with anti-IL-1 or anti-TNF-
antibodies 1 day before
and 7 days after reactivation.
RESULTS. UV-B irradiation stimulated an increase in corneal IL-1
mRNA in
reactivated (virus shedding) mice. This increase persisted longer and
was higher than in UV-B irradiated uninfected control animals. IL-1
and TNF-
protein in corneas of reactivated mice was significantly
elevated on days 3 to 10 compared with day 0 levels, and exceeded
levels in control corneas on the same days. Anti-IL-1 and anti-TNF-
antibody administration both resulted in significantly decreased
virus-induced corneal opacity between 7 and 21 days after UV-B
exposure.
CONCLUSIONS. IL-1
and TNF-
are upregulated in corneas in mice experiencing
recurrent HSK. Abrogation of virus-induced corneal disease by
anti-cytokine antibodies suggests that these cytokines play important
roles in the pathogenesis of recurrent disease. Therefore,
neutralization of specific proinflammatory cytokines may have potential
therapeutic value.
| Introduction |
|---|
|
|
|---|
The presence of HSV within the corneal stroma stimulates an
inflammatory response or keratitis. Herpetic stromal keratitis (HSK)
and attendant corneal lesions have been attributed to an
immunopathologic process that is orchestrated by T cells.2
Although T cells may play a key role in both tissue damage and repair,
their activity is modulated by the actions of other cells and
cytokines. Accordingly, the release of interleukin (IL)-1 and tumor
necrosis factor (TNF)-
from damaged corneal cells and infiltrating
cells may comprise an initial response to virus infection that
complements later T-cellmediated events.3
4
5
IL-1 is a potent proinflammatory cytokine produced by a variety of
cells including monocytes, macrophages, and corneal
cells.6
7
Among its functions are mediation of acute-phase
response, chemotaxis and activation of inflammatory and
antigen-presenting cells, upregulation of adhesion molecules,
enhancement of neovascularization, and the ability to serve as a
cofactor in lymphocyte activation.6
8
TNF-
is produced
mainly by activated macrophages and T cells but may also be made by
resident corneal cells.6
9
10
Many of its actions are
similar to and synergistic with that of IL-1.6
11
In the
eye, IL-1 and TNF-
activity has been associated with uveitis and the
corneal response to various types of injury.7
8
9
10
12
Recently, IL-1
expression was correlated with corneal opacity after
acute infection of the mouse eye with HSV.3
The exact
relationship between TNF-
and corneal HSV infection has not been
defined, but HSV-induced expression of both TNF-
and its receptors
by ocular cells and infiltrating inflammatory cells suggests a role for
this cytokine in HSK.4
5
13
We have characterized a murine model of recurrent HSK that mimics the
human disease.14
In this model, corneas of latently
infected mice exposed to UV-B irradiation experience recurrent viral
shedding and disease. As in humans, recurrent ocular disease in mice is
characterized by the appearance of microdendrites, focal stromal
opacification, endotheliitis, and neovascularization.1
15
In the present work, we quantitated IL-1
and TNF-
levels in
corneas of mice experiencing recurrent HSK and examined the effect of
anti-cytokine treatment on corneal opacity. We found that IL-1 and
TNF-
may play important parts in the immunopathogenesis of recurrent
corneal HSV infection.
| Materials and Methods |
|---|
|
|
|---|
Mice and Primary Infection
All investigations with mice conformed to the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research. Three-week-old
female NIH inbred mice were obtained from Harlan Olac (Oxford,
UK) and infected at 4 to 8 weeks of age. The eyes of all
mice were examined for corneal opacity before infection, and only
animals with clear corneas were used. Mice were infected with
106 plaque-forming units of HSV-1 McKrae strain,
as previously described.14
Concurrent with infection, each
mouse received an intraperitoneal injection of pooled human serum
(Chemicon, Temecula, CA; known to have anti-HSV reactivity with an
effective dose for 50% viral neutralization of 1:800) to protect
against corneal damage while permitting the establishment of latency.
UV-B Irradiation and Virus Reactivation
The eyes of all mice were examined for corneal opacity before
irradiation, and only animals with clear corneas were used. At least 5
weeks after primary infection (913 weeks of age), the eyes of
latently infected and control mock-infected mice were exposed to 170
mJ/cm2 UV-B light (TM20 Chromato-Vu
transilluminator; UVP, San Gabriel, CA; peak UV-B wavelength of 302
nm). Before (day 0), and on days 1 to 7 after UV-B irradiation, the
eyes of mice were swabbed with surgical spears (Weckcel; XomedTreace,
Jacksonville, FL), and the swab material was cultured on VERO cells to
detect recurrent virus shedding from the cornea. Reactivation was
defined as the finding of any HSV-positive eye swab on days 1 to 7
after UV-B exposure, with day 0 swabs serving as a control. In this
system, approximately 70% of UV-B irradiated corneas of latently
infected mice shed virus and characteristic corneal lesions develop,
including opacity.14
Virus-induced corneal opacification
typically peaks from 7 to 14 days after the reactivation stimulus.
Because previous work has established that nonvirus-shedding mice may
nevertheless harbor HSV in deep layers of the corneal stroma, data for
latently infected, nonreactivated mice are not included. Uninfected
eyes serve as a control for the transient effects of UV-B on corneal
opacity (peaking 3 to 7 days post irradiation) and cytokine induction
(clinical observation).
On the designated days after UV-B irradiation, eyes were evaluated for clinical disease by a masked observer using a dissecting microscope. Stromal opacification was rated on a scale of 0 to 4, where 0 indicates clear stroma, 1 indicates mild stromal opacification, 2 indicates moderate opacity with discernible iris features, 3 indicates dense opacity with loss of defined iris detail except pupil margins, and 4 indicates total opacity with no posterior view.
Enzyme-Linked Immunosorbent Assays
On specified days, corneas were removed from mice and frozen
individually at -80°C in media. On the day of assay, corneas were
thawed on ice, minced, sonicated for 30 seconds (Sonifer 450, Branson
Ultrasonics, Danbury, CT) and clarified by centrifugation to produce a
corneal lysate. For a given day after UV-B exposure, lysates from
reactivated mice (confirmed by virus-positive eye-swab data) were
pooled. Corneal lysates obtained from uninfected, UV-Birradiated mice
were included as controls. The cytokine assays performed for IL-1
and TNF-
used sandwich enzyme-linked immunosorbent assay (ELISA)
kits (Genzyme, Cambridge, MA) with a sensitivity of 15 pg/ml.
RNA Preparation
On specified days after UV-B irradiation, corneas were clinically
scored, excised as 2-mm corneal buttons, minced, and frozen separately
in TRIzol reagent (Life Technologies, Paisley, Scotland) at -80°C
until use. After confirmation of recurrent HSV shedding from eye-swab
data, reactivated corneas were pooled for each given day after UV-B
exposure, and total cellular RNA was prepared according to the
manufacturers directions for TRIzol reagent.
Reverse TranscriptionPolymerase Chain Reaction
The total cellular RNA for each day was reverse transcribed (RT)
according to RNA polymerase chain reaction (PCR) kit instructions
(GeneAmp; Perkin Elmer, Foster City, CA). Control reactions for each
day were performed in the absence of reverse transcriptase to ensure
purity of RNA preparations. The cDNA prepared from corneas was frozen
at -20°C and diluted as needed on the day of quantitation. PCR was
performed in a 50-µl reaction mixture containing 1x PCR buffer (60
mM Tris-HCl [pH 8.5], 15 mM
(NH4)SO4, 3.5 nM
MgCl2; Invitrogen: San Diego, CA), 400 µM dNTP
mixture (Perkin ElmerRoche, Branchburg, NJ), 0.5 U Taq DNA
polymerase (AmpliTaq, Perkin ElmerRoche), 5% dimethyl
sulfoxide (Sigma, St. Louis MO), 6 to 8 picomoles of primers, and 10
µl cDNA (from RT reaction), with or without competitor plasmid. The
PCR protocol consisted of 35 cycles of denaturation at 95°C for 30
seconds, annealing at 57°C for 30 seconds, and extension at 72°C
for 2 minutes. The reaction mixture was prepared as a master mixture to
minimize reaction variation.
Qualitative PCR Analysis of Cytokine mRNA Expression
Part of the cDNA preparation for each experimental sample was used
initially in a qualitative PCR to analyze the expression pattern of
TNF-
, IL-1
, and the constitutively expressed peripheral
benzodiazepine receptor (BzR). For each primer set, undiluted cDNA from
every sample day was evaluated by PCR, as described, without competitor
plasmid. Results were used to determine the presence or absence of a
given mRNA species on each day and to gauge the amount of competitor to
be used for quantitative PCR. The expression level of IL-1
mRNA
present in each cDNA sample was subsequently quantified using a
competitor plasmid in quantitative PCR. RNA from concanavalin
Astimulated T cells was used as a positive control.
PCR Primers and Competitor Plasmids for Quantitative PCR
A competitor plasmid (pMUS) contained a multispecific primer
cassette with primer binding sites for IL-1
, TNF-
, BzR, and other
cytokines.16
Primer sequences were: IL-1
sense,
5'-CAGTTCTGCCATTGACCATC-3'; IL-1
antisense, 5'-TCTCAC
TGAAACTCAGCCGT-3'; TNF-
sense, 5'-TCTCATCAGTTCTATGGCCC-3'; TNF-
antisense, 5'-GGGAGTAGACAAGGTACAAC-3'; and BzR sense, 5'-TCTGGAAA
GAGCTGGGAGG-3'; BzR antisense, 5'-AAGGCCAGCCAGGCCAGG-3'. Primers were
designed to span introns. Amplified products from cDNA (218 bp for
IL-1
, 212 bp for TNF-
, 237 bp for BzR) and competitor templates
(320 bp) differed in size by approximately 100 bp. Using these primers,
the detection limit of mRNA molecules at 35 cycles was less than 100
molecules, as determined in preliminary experiments.
Quantitative PCR
The level of IL-1
transcripts was determined by competitive PCR
as described using the multispecific competitor plasmid
pMus.16
17
Briefly, a constant amount of the sample cDNA
was coamplified with the IL-1
primers in 6 to 10 reactions along
with varying amounts of the competitor. In these reactions, specific
primers compete for annealing and amplification of the competitor
plasmid and cellular cDNA, resulting in products that differ by
approximately 100 bp. Amplification was performed in the exponential
phase as determined in preliminary experiments. After amplification,
the competitor and the cytokine products were separated on a 12%
polyacrylamide gel and stained with ethidium bromide. The intensities
of the amplified products were measured by video densitometry (model
GS-670 imaging densitometer with molecular Analyst/PC image analysis
software, Bio-Rad, Hercules, CA). To adjust for the effect of molecular
weight differences on band intensities, the target cytokine intensity
was normalized to the competitor product intensity. The log ratios of
the normalized target intensity to the competitor intensity were
plotted against the log of the number of competitor molecules. The
amount of IL-1
mRNA present in the volume of cDNA used for
quantification was determined from the plot, where the
target-competitor ratio was 1. Representative quantitative PCR results
are presented in Figure 1
. BzR mRNA was quantified along with IL-1
mRNA and served as a
control for RNA preparation and the temporal comparison of mRNA
species.
|
(TN3.19.12), IL-1
(ALF
161.1), IL-1 ß (B122), and IL-1 R (JAMA 147) were kindly provided by
Robert Schreiber, Washington University School of Medicine (St. Louis,
MO). Hamster immunoglobulin (Ig)G whole molecule control was obtained
from Accurate Chemical and Scientific (Westbury, NY). Antibodies were
administered to latently infected mice subconjunctivally (40 µg total
protein: 13.33 µg of each antibody for IL-1; 40 µg total protein
for TNF-
) and intraperitoneally (690 µg total protein: 230 µg of
each antibody for IL-1; 230 µg total protein for TNF-
) on day 0
and intraperitoneally (450 µg total protein: 150 µg of each
antibody for IL-1; 150 µg total protein for TNF-
) on day 7 after
UV-B exposure. Doses of antibody were based on the recommendation and
experience of R. Schreiber. Recurrent virus shedding (reactivation) and
corneal opacity was assessed, as described.
Statistical Analysis
Linear regression used for mRNA quantitation was performed with
the aid of Sigmaplot 4.0 (Jandel, Corte Madera, CA). Students
t-tests and the MannWhitney rank sum test were used as
appropriate to analyze ELISA and opacity data.
| Results |
|---|
|
|
|---|
expression in a mouse model of
recurrent HSK. Table 1
presents quantitative data for IL-1
mRNA in reactivated
and uninfected corneas before (day 0), and up to 21 days after exposure
to 170 mJ/cm2 UV-B irradiation. Although present in both
groups, IL-1
mRNA per cornea of reactivated mice surpassed that of
control animals from day 5 onward in each experiment, reaching up to
two- to threefold higher levels. In addition, the UV-B increase in
IL-1
message persisted longer in reactivated corneas (days 5, 7, and
14) than in uninfected control corneas (day 3 or 5). When IL-1
message for each day was normalized to the expression of the
constitutive peripheral benzodiazepine receptor (BzR), similar results
were obtained (Table 1)
, with even greater disparity between
reactivated and control corneas (differences more than fourfold) on
days 5 to 21. Although not quantitated, strong TNF-
mRNA bands were
observed in control and reactivated corneas on qualitative PCR gels.
|
and TNF-
Expression after UV-BInduced HSV Reactivation
protein in uninfected control animals, whereas corneas of
reactivated mice demonstrated a significant increase in IL-1
from
days 3 to 10 (P < 0.01 for all time points) that
returned to control levels by day 14 (Fig. 2)
. Similarly, corneas of
reactivated mice contained significantly more TNF-
protein than did
uninfected controls from day 3 to day 10 (P =
0.0060.030) and returned to control levels by day 14 (Fig. 3)
.
|
|
Neutralization on Recurrent HSK
in the pathogenesis of recurrent HSK, we administered
specific antibodies directed against these cytokines to latently
infected mice before reactivation. Antibodies (anti-TNF-
or a
cocktail of anti-IL-1
, anti-IL-1ß, and anti-IL-1 receptor) were
injected into mice on day 0 and day 7 relative to UV-B exposure. As
Figure 4 indicates, both antibody preparations demonstrated therapeutic efficacy
when compared with mice receiving the isotype-matched hamster antibody
control. Significantly reduced corneal opacity was noted for the
anti-IL-1 cocktail on days 7 (P = 0.011) and 21
(P = 0.05) and on days 14 (P = 0.016)
and 21 (P = 0.045) for the anti-TNF-
antibody. The
number of mice shedding virus after UV-B irradiation was 7 of 10 in the
anti-cytokine groups and 10 out of 10 in the hamster antibody control
group. Thus, although we did not rule out anti-cytokine antibody
effects on virus titer in tear films or tissues, there was no
significant change (P = 0.44) in the ability of HSV to
reactivate after UV-B irradiation.
|
| Discussion |
|---|
|
|
|---|
in primary or
recurrent HSK.
The present work demonstrates that recurrent HSV infection induced
expression of IL-1
and TNF-
in murine corneas (Table 1
, Figs. 2
and 3
). In comparison, uninfected, UV-B irradiated corneas did not
substantially increase levels of these cytokines. Research in primary
ocular HSV infection models supports our findings for IL-1, but results
for TNF-
have been variable. In one study, IL-1
protein was
readily detected in corneal lysates after acute infection with HSV,
whereas significant amounts of TNF-
could not be found
.3
In contrast, work by other researchers has demonstrated
TNF-
production by HSV-primed ocular cells in response to HSV in
vitro and TNF-
mRNA induction in HSV-infected
corneas.4
5
Although IL-1
protein was detected in
primary HSK in relatively high amounts up to 20 days after infection,
levels of the cytokine in recurrent HSK returned to baseline by 14 days
after UV-B exposure (Fig. 2) .3
Apart from mouse and virus
strain differences, this inequity may reflect the fact that recurrent
ocular HSV infection in mice and humans is a focal disease that does
not characteristically progress to necrotizing keratitis.
In addition to resident corneal cells, likely sources of TNF-
and
IL-1
in recurrent HSK are the inflammatory cells that invade the
cornea in response to the renewed presence of HSV. Indeed, earlier work
in our laboratory and others, has shown that macrophages, Langerhans
cells, T cells and polymorphonuclear cells (PMNs) infiltrate
the corneas of mice experiencing recurrent HSK and may serve as
potential sources of IL-1 and TNF-
.15
19
Thus, our
previous report of centripetal migration of macrophages into the
central cornea starting within 3 days of the reactivation stimulus
correlates well with the increases in IL-1
and TNF-
that we
observed on day 3 in the present study (Figs. 2
and 3) .15.
Similarly, large numbers of PMNs invading the corneal stroma of
virus-shedding mice within 4 days of UV-B irradiation could be a
significant source of the two cytokines.19
20
Levels of
IL-1 and TNF-
would be further augmented by the influx of
cytokine-producing Langerhans cells and T cells occurring by 7 days
after reactivation.15
21
Fewer infiltrating cells in
uninfected UV-B control corneas may account for the relatively small
amounts of the proinflammatory cytokines detected (Figs. 2
and 3)
.19
IL-1 and TNF-
may contribute to the corneal disease of recurrent HSK
in numerous ways based on known properties of the two cytokines. After
virus-associated tissue damage, local release of IL-1 and/or TNF-
would trigger a series of events including an increase in the activity
of inflammatory mediators such as prostaglandins, leukotrienes, and
nitric oxide.6
At the same time, upregulation of cell
adhesion molecules and chemoattraction by IL-1 and TNF-
would
promote the accumulation of PMNs, macrophages, Langerhans cells, and
lymphocytes at sites of viral recurrence. Enhanced production of IL-1
and TNF-
by infiltrating cells could boost synthesis of chemokines,
such as IL-8 and macrophage inflammatory protein-1
, which have been
associated with recruitment and activation of PMNs and T cells in
HSK.22
23
24
Neutrophils, the most prominent infiltrating
cell type seen in HSK, are thought to play a crucial role in tissue
damage and may perpetuate corneal inflammation by exposing neoantigens
subject to T-cell responses.19
25
With regard to T
cell function, IL-1 and TNF-
could enhance virus-specific or
nonspecific activation.6
Studies of corneal allografting and primary ocular HSV infection have
recently illustrated the importance of IL-1 in mediating corneal
disease. Thus, grafted corneal buttons treated with IL-1 receptor
antagonist are less opaque and more frequently accepted by
recipients.18
Similarly, treatment of mice with protective
anti-glycoprotein D antibodies at the time of initial ocular infection
with HSV-1 diminishes both corneal disease and the presence of IL-1
in infected corneas.3
Here we have directly examined the
importance of IL-1 and TNF-
in recurrent HSK by using specific
neutralizing antibodies. We found that treatment with anti-IL-1 or
anti-TNF-
antibodies decreased postreactivation corneal opacity up
to 2 weeks after the last injection (Fig. 4 , day 21). This protective
effect may result from decreased IL-1
and TNF-
activity as well
as the loss of synergistic interaction between the two
cytokines.6
11
Thus, although IL-1 was dominant in the
absolute quantity present in reactivated corneas (Fig. 2) , TNF-
could indirectly influence disease outcome by boosting IL-1 effects.
Loss of this cooperative interaction would manifest as a decrease in
corneal opacity in anti-TNF-
treated mice (Fig. 4)
. Although there
are many possibilities (as outlined earlier), diminished inflammatory
cell infiltration and function may account for a large part of the
decline in corneal disease seen in antibody-treated mice. Given the
hypothesized importance of T cells and PMNs in the immunopathogenesis
of HSK, such a limitation could easily diminish downstream corneal
disease.2
25
In summary, we examined the role of IL-1 and TNF-
in a mouse model
of recurrent HSK with many similarities to the human disease. For both
mice and humans, these cytokines are among the first to be produced or
released when the cornea is damaged.7
9
In the context of
recrudescent ocular HSV infection, IL-1 and TNF-
may directly
contribute to corneal damage and stimulate or amplify later
cell-mediated events. Amelioration of corneal opacity by blocking
antibodies underscores the importance of these cytokines in at least
the initiation of corneal lesions. The role of T cells in mediating
recurrent HSK is currently under investigation in this laboratory.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication March 18, 1999; revised June 28, 1999; accepted August 6, 1999.
Commercial relationships policy: N.
Corresponding author: Jay S. Pepose, BJC Health Center, 16216 Baxter Road, Suite 205, Chesterfield, MO 63017.
| References |
|---|
|
|
|---|
knockout mice J Immunol 155,3964-3970[Abstract]
prevents the development of blinding herpes stromal keratitis J Virol 72,3705-3710This article has been cited by other articles:
![]() |
K. Kimura, S. Teranishi, K. Fukuda, K. Kawamoto, and T. Nishida Delayed Disruption of Barrier Function in Cultured Human Corneal Epithelial Cells Induced by Tumor Necrosis Factor-{alpha} in a Manner Dependent on NF-{kappa}B Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 565 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lundberg, P. V. Welander, C. K. Edwards III, N. van Rooijen, and E. Cantin Tumor Necrosis Factor (TNF) Protects Resistant C57BL/6 Mice against Herpes Simplex Virus-Induced Encephalitis Independently of Signaling via TNF Receptor 1 or 2 J. Virol., February 1, 2007; 81(3): 1451 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bitko, A. Musiyenko, and S. Barik Viral Infection of the Lungs through the Eye J. Virol., January 15, 2007; 81(2): 783 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Heiligenhaus, H. F. Li, Y. Yang, S. Wasmuth, K. P. Steuhl, and D. Bauer Transplantation of Amniotic Membrane in Murine Herpes Stromal Keratitis Modulates Matrix Metalloproteinases in the Cornea Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4079 - 4085. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Hao, K. Suzuki, Y. Lu, S. Hirano, K. Fukuda, N. Kumagai, K. Kimura, and T. Nishida Inhibition of Gap Junction-Mediated Intercellular Communication by TNF-{alpha} in Cultured Human Corneal Fibroblasts Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1195 - 1200. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamagami, S. Yokoo, T. Mimura, and S. Amano Effects of TGF-{beta}2 on Immune Response-Related Gene Expression Profiles in the Human Corneal Endothelium Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 515 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wasmuth, D. Bauer, Y. Yang, K.-P. Steuhl, and A. Heiligenhaus Topical Treatment with Antisense Oligonucleotides Targeting Tumor Necrosis Factor-{alpha} in Herpetic Stromal Keratitis Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5228 - 5234. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamagami, S. Yamagami, T. Inoki, S. Amano, and K. Miyata The Effects of Proinflammatory Cytokines on Cytokine-Chemokine Gene Expression Profiles in the Human Corneal Endothelium Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 514 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Koelle and L. Corey Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research Clin. Microbiol. Rev., January 1, 2003; 16(1): 96 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Maertzdorf, A. D. M. E. Osterhaus, and G. M. G. M. Verjans IL-17 Expression in Human Herpetic Stromal Keratitis: Modulatory Effects on Chemokine Production by Corneal Fibroblasts J. Immunol., November 15, 2002; 169(10): 5897 - 5903. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ellermann-Eriksen and V. Kruys Expression of TNF-{alpha} by Herpes Simplex Virus-Infected Macrophages Is Regulated by a Dual Mechanism: Transcriptional Regulation by NF-{kappa}B and Activating Transcription Factor 2/Jun and Translational Regulation Through the AU-Rich Region of the 3' Untranslated Region J. Immunol., August 15, 2001; 167(4): 2202 - 2208. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Stumpf, C. Shimeld, D. L. Easty, and T. J. Hill Cytokine Production in a Murine Model of Recurrent Herpetic Stromal Keratitis Invest. Ophthalmol. Vis. Sci., February 1, 2001; 42(2): 372 - 378. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |